1. REPLY TO MA AND WANG: Reliability of various in vitro activity assays on SARS-CoV-2main protease inhibitors.
- Author
-
Zhe Li, Yuxi Lin, Yi-You Huang, Runduo Liu, Chang-Guo Zhan, Xin Wang, and Hai-Bin Luo
- Subjects
- *
PROTEASE inhibitors , *COMMERCIAL products - Abstract
LETTER REPLY TO MA AND WANG: Reliabilityofvariousinvitroactivityassayson SARS-CoV-2mainproteaseinhibitors Zhe Li a,1 , Yuxi Lin b,c,1, Yi-You Huang a,1, Runduo Liu a , Chang-Guo Zhan d,e,2 , Xin Wang b,f,2 , and Hai-Bin Luo a,g,2 Ma and Wang (1) tested our recently reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) main protease (M pro) noncovalent inhibitors (2) using their in vitro assays, and they obtained negligible or much lower inhibitory activities compared to ours. Notably,thefluorescence resonanceenergytransfer(FRET)-basedenzymaticassay used by Ma and Wang (1) is different from our FRETbased enzymatic assay in the M pro protein (discussed below) and the FRET substrate [longer than the more popularly used substrate (3, 4) utilized in our assay]. Ma and Wang (1) also used native mass spectrometry (MS) and thermal shift assays (TSA) to detect the protein-ligand binding. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF